2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4299 Time of day for hematopoietic cell infusion does not impact outcomes in allogeneic transplantation

Jason Sean Gilbert, MD, Megan Othus, PhD2, Chris Davis3, Ryan Basom4, Linda Glockling5, Geoff R Hill, MD6, Filippo Milano I, MD, PhD7
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background:

Recent studies suggest that the time of day a patient receives cell therapy as treatment for malignancy, including allogeneic hematopoietic cell transplantation (HCT), affects outcomes (Hou Y et al, Cell 2025). These studies posit that earlier in the day cell infusion reduces acute graft-versus-host-disease (aGVHD) and improves overall survival (OS), purportedly due to circadian-driven increases in IL-1 later in the day. Given the large effect sizes, and that well-designed double-blind randomized studies of IL-1 inhibition during HCT have failed to show any benefit (Antin JH et al, Blood 2002), we investigated this association in a large contemporary HCT cohort at the Fred Hutchinson Cancer Center.

Methods:

Using an IRB-approved institutional database, we retrospectively reviewed and analyzed all patients who underwent allogeneic HCT at Fred Hutchinson Cancer Center between January 2021 and December 2025. Patients undergoing a second transplant were excluded. To reflect prior studies, patients were stratified into two groups: those who received their stem cell infusion before 2:00 PM, and those who received the infusion after 2:00 PM. Infusion times were extracted using nursing documentation in the electronic health record. Statistical analyses included Kaplan-Meier and non-parametric cumulative incidence estimation, descriptive evaluation of Martingale residuals, log-rank and Gray’s tests, and Cox and cause-specific regression models to evaluate OS, disease-free survival (DFS), relapse, aGVHD, chronic graft-versus-host-disease (cGVHD), neutrophil engraftment, and platelet recovery.

Results:

A total of 738 patients were included, comprising 368 patients who received the stem cell infusion before 2:00 PM (“before” group) and 370 patients who received the infusion after 2:00 PM (“after” group). Patients in the before group were younger (59 vs 64 years old, p<0.001), more likely to have received grafts from matched-related donors (19% vs 12%, p<0.001) and CMV-seropositive donors (52% vs 44%, p=0.038), more likely to undergo myeloablative conditioning (51% vs 31%, p<0.001), and less likely to receive post-transplant cyclophosphamide (39% vs 47%, p<0.001). The groups did not differ in sex, diagnosis, donor sex, recipient ABO blood type, donor ABO blood type, recipient CMV status, total body irradiation dose, or infused cells dose.

Myelodysplasia (versus ALL; HR 2.01, p=0.042) and reduced intensity conditioning (versus myeloablative conditioning; HR 1.52, p=0.038) were associated with worse OS in multivariable analyses.  Post-transplant cyclophosphamide was associated with reductions in cGVHD versus methotrexate-based GVHD prophylaxis (HR 0.40, p<0.001) that did not translate to improvements in OS. On univariate analysis, stem cell infusion before or after 2:00 PM was not associated with OS (p=0.44), aGVHD (p=0.35), cGVHD (p=0.59), DFS (p=0.17), relapse (p=0.57), neutrophil engraftment (p=0.89), or platelet recovery (p=0.059). In multivariable analysis, the time of stem cell infusion also was not associated with OS (HR 0.91, p=0.44), grade III-IV aGVHD (HR 0.68, p=0.10), any cGVHD (HR 1.01, p=0.91), DFS (HR 1.01, p=0.91) or relapse (HR 1.06, p=0.76).

Conclusions:

In this large contemporary transplant cohort, the timing of stem cell infusion for allogeneic HCT was not associated with survival, GVHD, relapse, or hematopoietic recovery. Significant baseline differences between patients receiving infusions before and after 2:00 PM were noted, but no statistically significant or meaningful differences in clinical outcomes were identified in multivariable analyses. In the absence of prospective randomized data, we conclude that timing hematopoietic cell infusions to a particular time of day should not be prioritized with the expectation of modifying clinical outcomes.  

Jason Sean Gilbert, MD: No relevant conflicts of interest to declare.